May 22 |
Soleno Therapeutics to Participate in Upcoming Investor Conferences
|
May 15 |
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
|
May 10 |
Soleno a new outperform at Baird on lead candidate for Prader-Willi syndrome
|
May 9 |
Soleno Therapeutics GAAP EPS of -$0.59 misses by $0.22
|
May 9 |
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
May 8 |
While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most
|
May 3 |
Soleno Therapeutics announces pricing of $138M public offering
|
May 3 |
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
|
May 2 |
Soleno Therapeutics announces proposed common stock offering
|
May 2 |
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
|